To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

You are entering to Sanofi Content Site

You are about to leave the T1D website

Welcome to the T1D Step Ahead Sanofi website

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

dyslipidaemia

Dyslipidaemia

This session provided insights from the scientific statement put forward by the National Lipid Association on genetic testing in dyslipidemia, published in 2020; the statement paper discusses mainly the applications of genetic testing in patients with dyslipidemias and laboratory methods; technical, biological, clinical, and ethical implications.

<h2>Key Takeaway</h2>
<ul>
 <li>Genetic testing is increasingly becoming a common consideration in the clinical care of patients with dyslipidemia.</li>
 <li>Dyslipidemias for which genetic testing could be clinically useful include FH and other monogenic and polygenic lipid disorders</li>
 <li>Confirming a diagnosis of monogenic dyslipidemia using genetic testing can affect management and screening to identify affected family members, termed “cascade screening”, for example, as has been well defined in FH.</li>
 <li>Other potential benefits of genetic testing include guiding optimal management and prevention strategies, advancing care strategies beyond currently available treatments, identi¬fying affected family members, and contributing to scientific progress*.</li>
</ul>

<h2>Why This Matters</h2>
<ul>
 <li>Genetic testing can help diagnosing dyslipidemias with underlying DNA mutations (variants).</li>
 <li>However, clinical indications for genetic testing for most dyslipidemias are not clearly established and currently no guidelines exist.</li>
</ul>

<h2>Key Results</h2>
What are monogenic and polygenic dyslipidemias? 
 Monogenic dyslipidemias:
<ul>
 <li>Rare, large-effect DNA variants (mutations) that cause monogenic/Mendelian dyslipidemias, with FH being the most common Polygenic dyslipidemias:</li>
</ul>
Polygenic dyslipidemias:
<ul>
 <li>Result from concurrent contributions of multiple common variants whose aggregate effect on lipoprotein levels can resemble large-effect rare variant</li>
 <li>Inheritance does not follow Mendelian rules</li>
 <li>Impact of such common variant is quantified using a polygenic score</li>
 <li>Clinical utility of polygenic score is not clear</li>
</ul>
What are the potential indications for genetic testing in dyslipidemia?
<ul>
 <li>Strong clinical suspicion of a genetic dyslipidemia</li>
 <li>Strong family history of dyslipidemia or its complications</li>
 <li>Presence of related syndromic features</li>
 <li>Evidence that testing might change the management</li>
 <li>Existence of available and effective early interventions</li>
 <li>Eligibility for new or investigational drugs</li>
 <li>Patient preference</li>
 <li>Family planning</li>
 <li>Other indications, including different therapies depending on results, access to specialized therapies, and insurance coverage</li>
</ul>
What are the potential outcomes of genetic testing in dyslipidemia?
<ul>
 <li>Aid in clinical diagnosis and targeted treatment of specific disorders</li>
 <li>Guide optimal management and prevention strategies</li>
 <li>Increase patient compliance and motivation</li>
 <li>Provide early identification of affected family members through cascade screening</li>
 <li>Contribute to scientific advancement</li>
 <li>Indication for access to novel therapies</li>
 <li>Eligibility for insurance coverage for certain therapies</li>
</ul>
What should be considered while planning genetic testing?
<ul>
 <li>Intensity of FH treatment should be guided by LDL-C elevation rather than the underlying genotype</li>
 <li>Not all genetic tests are created equal</li>
 <li>Review analytic and clinical validity of a test prior to medical management decisions</li>
 <li>Attributing pathogenicity to a DNA variant can differ between laboratories</li>
 <li>Confirmation using clinical genetic test is recommended to avoid false-positive/false-negative results by direct-to-consumer genetic testing</li>
 <li>Polygenic scores for dyslipidemia are not standardized and not recommended or appropriate for clinical use in dyslipidemia</li>
</ul>
What are the components of genetic counselling? 
 Genetic counselling is offered to patients and their families before and after genetic testing.
Before ordering a genetic test:
<ul>
 <li>Obtain an informed consent form</li>
 <li>Counsel the patient regarding the risk and benefits of genetic testing After ordering a genetic test:</li>
</ul>
After ordering a genetic test:
<ul>
 <li>Test results should be disclosed by a clinician with expertise in genetics or by a certified genetic counselor</li>
 <li>Genetic counselling should be provided to patients and their families even if the results are negative</li>
 <li>Definitive incidental findings in certain genes that are unrelated to lipids should also be communicated to the patients</li>
 <li>Results should be tailored to the patient-specific circumstances, level of understanding, and literacy</li>
</ul>
<a href="https://www.lipid.org/nla/genetic-testing-dyslipidemia" target="_blank">*Infographic</a>

Abbreviations

Reference

Role of Genetic Testing in Management of Dyslipidemia

DYSLIPIDEMIA

CARDIOLOGY

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Watch the video tackling the critical topic of dyslipidemia management post-acute coronary syndrome. Globally, despite its pivotal role in secondary prevention, the approach remains suboptimal, so we'll dissect Arafah MR et al recent publication, providing a detailed evaluation of lipid management after ACS in Saudi Arabia. Specifically, shining a spotlight on LDL-cholesterol management and delve into the complications of statin use in post-ACS Saudi patients.

Managing the Recurrent ASCVD Risks of Your ACS Patient: Gulf Perspective (Part 1)

Atherosclerosis cardiovascular disease (ASCVD) is now a leading cause of death internationally and locally. It’s a risk for patients who have acute coronary syndrome, which is a medical emergency that requires immediate attention. Professor Mohamed Balgaith, an interventional cardiologist at King Abdulaziz Cardiac Center National Guard Riyadh, highlights the effect of atherosclerosis, cardiovascular disease burden, and the risks of recurring ischemic events post-Acute Coronary Syndrome, watch the video to learn more.

Dyslipidaemia

Latest Articles

Role of Genetic Testing in Management of Dyslipidemia

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Managing the Recurrent ASCVD Risks of Your ACS Patient: Gulf Perspective (Part 1)